Chlormethine gel is effective for the treatment of skin lesions in patients with early‐ and late‐stage mycosis fungoides in clinical practice

Chlormethine gel is a skin‐directed therapy used for patients with mycosis fungoides (MF) that showed a favourable risk/benefit profile in a randomized clinical trial. Currently, data on chlormethine gel use in real‐world settings are limited.

[1]  I. Amitay-Laish,et al.  Real-life experience with chlormethine gel for early-stage mycosis fungoides with emphasis on types and management of cutaneous side-effects# , 2021, The Journal of dermatological treatment.

[2]  J. Scarisbrick,et al.  Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA–IIA Mycosis Fungoides , 2021, Dermatology.

[3]  E. Papadavid,et al.  Chlormethine Gel in Combination with Other Therapies in the Treatment of Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: Three Case Reports , 2021, Advances in Therapy.

[4]  O. Akilov,et al.  The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma , 2021, American Journal of Clinical Dermatology.

[5]  Ellen J. Kim,et al.  Evaluating the Treatment Patterns of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: By-time Reanalysis of a Randomized Controlled Phase 2 Study. , 2020, Clinical lymphoma, myeloma & leukemia.

[6]  B. Poligone,et al.  Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis , 2020, JAAD case reports.

[7]  P. Porcu,et al.  Skindex-29 scores indicate poor quality of life in early stage mycosis fungoides. , 2020, Journal of dermatological science.

[8]  D. Buckley,et al.  British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018 , 2018, The British journal of dermatology.

[9]  J. Scarisbrick,et al.  Update on skin directed therapies in mycosis fungoides. , 2019, Chinese clinical oncology.

[10]  C. Klemke,et al.  European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. , 2017, European journal of cancer.

[11]  Marianne Tawa,et al.  Optimizing Care and Compliance for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel. , 2015, Clinical journal of oncology nursing.

[12]  C. Prinsen,et al.  Interpretation of Skindex-29 scores: cutoffs for mild, moderate, and severe impairment of health-related quality of life. , 2011, Journal of Investigative Dermatology.

[13]  M. Chren,et al.  Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. , 1997, Archives of dermatology.

[14]  Hodgkin Lymphoma NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .

[15]  B. Strober,et al.  Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. , 2013, JAMA dermatology.

[16]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .